{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:24:38Z","timestamp":1778243078951,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:p> This study investigated whether serious adverse events (SAEs) during antituberculosis therapy occur more frequently in HIV co-infected patients in a South African population. A retrospective analysis examined incidences of hepatotoxicity, peripheral neuropathy, severe arthralgia, persistent vomiting and severe rash in 400 patients treated for tuberculosis in a community clinic. A total of 141 patients were co-infected with HIV, among whom only 16.3% were receiving antiretrovirals. Details of SAEs were ascertainable in 331\/400 patients, and occurred in 26.7% of HIV-infected and 13.3% of HIV-uninfected individuals ( P = 0.003). The excess was attributable to increased peripheral neuropathy (8.3% and 1.9%, respectively, P = 0.009) and persistent vomiting (13.3% and 3.3%, P = 0.001). SAE occurrence was not related to antiretroviral use, although median CD4 counts were lower in those experiencing side-effects (130 and 259 cells\/\u00b5L, P = 0.008). The treatment completion did not differ significantly between the two groups (76.6% and 84.2%, P = 0.08). <\/jats:p>","DOI":"10.1258\/ijsa.2008.008361","type":"journal-article","created":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T18:06:55Z","timestamp":1240423615000},"page":"339-345","source":"Crossref","is-referenced-by-count":65,"title":["Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs"],"prefix":"10.1177","volume":"20","author":[{"given":"D J B","family":"Marks","sequence":"first","affiliation":[{"name":"Centre for Molecular Medicine, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Dheda","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa"},{"name":"Centre for Infectious Diseases and International Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Dawson","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Ainslie","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R F","family":"Miller","sequence":"additional","affiliation":[{"name":"Research Department of Infection and Population Health, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2009,5,1]]},"reference":[{"key":"bibr-IJSA-08-361C1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68770-9"},{"key":"bibr-IJSA-08-361C2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68383-9"},{"key":"bibr-IJSA-08-361C3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.4.380"},{"key":"bibr-IJSA-08-361C4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69573-1"},{"key":"bibr-IJSA-08-361C5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200206-626OC"},{"key":"bibr-IJSA-08-361C6","first-page":"123","volume":"1","author":"Pedral-Sampaio DB","year":"1997","journal-title":"Braz J Infect Dis"},{"key":"bibr-IJSA-08-361C7","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200201040-00010"},{"key":"bibr-IJSA-08-361C8","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.058867"},{"key":"bibr-IJSA-08-361C9","volume-title":"The Western Cape Antiretroviral Programme: Monitoring Report","author":"Western Cape Department of Health","year":"2006"},{"key":"bibr-IJSA-08-361C10","volume-title":"Models of Care for Antiretroviral Service Delivery","author":"Pienaar D","year":"2006"},{"key":"bibr-IJSA-08-361C11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-6-22"},{"key":"bibr-IJSA-08-361C12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(06)70628-4"},{"key":"bibr-IJSA-08-361C13","volume-title":"Table for Grading Severity of Adult Adverse Experiences","author":"AIDS Clinical Trials Group","year":"1996"},{"key":"bibr-IJSA-08-361C14","unstructured":"WHO. International Monitoring or Adverse Reactions to Drugs: Adverse Reaction Terminology. WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden, 1992"},{"key":"bibr-IJSA-08-361C15","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000238406.93249.cd"},{"key":"bibr-IJSA-08-361C16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.00758.x"},{"key":"bibr-IJSA-08-361C17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2000.00287.x"},{"key":"bibr-IJSA-08-361C18","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyh021"},{"key":"bibr-IJSA-08-361C19","doi-asserted-by":"publisher","DOI":"10.1086\/444463"},{"key":"bibr-IJSA-08-361C20","doi-asserted-by":"publisher","DOI":"10.1086\/422724"},{"key":"bibr-IJSA-08-361C21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2007.01871.x"},{"key":"bibr-IJSA-08-361C22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200510-1666ST"},{"key":"bibr-IJSA-08-361C23","first-page":"1296","volume":"127","author":"Lobato MN","year":"2005","journal-title":"Chest"},{"key":"bibr-IJSA-08-361C24","doi-asserted-by":"publisher","DOI":"10.1159\/000109826"},{"key":"bibr-IJSA-08-361C25","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(80)90038-0"},{"key":"bibr-IJSA-08-361C26","first-page":"1122","volume":"4","author":"Baum MK","year":"1991","journal-title":"J Acquir Immune Defic Syndr"},{"key":"bibr-IJSA-08-361C27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2006.03319.x"},{"key":"bibr-IJSA-08-361C28","doi-asserted-by":"publisher","DOI":"10.1136\/jech.2005.044404"},{"key":"bibr-IJSA-08-361C29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68387-6"},{"key":"bibr-IJSA-08-361C30","doi-asserted-by":"publisher","DOI":"10.1086\/424676"},{"key":"bibr-IJSA-08-361C31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69117-4"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1258\/ijsa.2008.008361","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1258\/ijsa.2008.008361","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1258\/ijsa.2008.008361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T05:38:56Z","timestamp":1740980336000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1258\/ijsa.2008.008361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1258\/ijsa.2008.008361"],"URL":"https:\/\/doi.org\/10.1258\/ijsa.2008.008361","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}